TABLE 4.
Prognostic Factors for Response and Survival
| Characteristic | Response, % | P | 1-Year Survival, % |
P |
|---|---|---|---|---|
| Age, y | ||||
| <60 | 18 | 14 | ||
| ≥60 | 19 | .60 | 7 | .18 |
| Response to prior therapy, frontline/salvage 1 |
||||
| CR/CR | 25 | 19 | ||
| CR/no CR | 13 | 8 | ||
| No CR/CR | 15 | .096 | 15 | .001 |
| No prior CR | 32 | 19 | ||
| Duration of first CR, mo | ||||
| 0 | 25 | 19 | ||
| 1-11 | 12 | 6 | ||
| 12-35 | 19 | .016 | 14 | <.001 |
| ≥36 | 44 | 44 | ||
| Karyotype | ||||
| Diploid | 18 | 10 | ||
| Philadelphia-positive | 20 | .67 | 9 | .42 |
| Other | 17 | 16 | ||
| Hemoglobin, g/dL | ||||
| <10 | 11 | <.001 | 8 | <.001 |
| ≥10 | 28 | 20 | ||
| WBC, × 109/L | ||||
| <5 | 20 | 14 | ||
| 5-20 | 23 | .15 | 19 | .002 |
| >20 | 9 | 6 | ||
| Percentage bone marrow blasts | ||||
| <20 | 32 | 29 | ||
| 20-50 | 31 | .013 | 22 | .001 |
| >50 | 14 | 12 | ||
| Percentage peripheral blasts | ||||
| 0 | 31 | 20 | ||
| 1-10 | 19 | .008 | 14 | .013 |
| >10 | 12 | 12 | ||
| Platelets, × 109 | ||||
| <25 | 7 | 7 | ||
| 25-50 | 10 | <.001 | 10 | <.001 |
| >50 | 28 | 20 | ||
| Albumin, g/L | ||||
| <3 | 11 | 2 | ||
| ≥3 | 21 | <.001 | 17 | <.001 |
| Immunophenotype | ||||
| B-cell origin | 19 | 14 | ||
| T-cell origin | 20 | .91 | 12 | .72 |
| Unknown/not done | 17 | 14 | ||
| Year of study | ||||
| 1980-1991 | 24 | .02 | 14 | .96 |
| 1992-2007 | 14 | 14 | ||
| Salvage 2 | ||||
| VAD/hyper-CVAD cytarabine combinations, allogeneic transplantation |
31 | <.001 | 19 | .004 |
| Other | 7 | 10 |
CR indicates complete response; WBC, white blood cell count; VAD, vincristine, doxorubicin, and dexamethasone; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.